We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ascribe | LSE:ABE | London | Ordinary Share | GB00B04WW503 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | GBX |
Ascribe (ABE) Share Charts1 Year Ascribe Chart |
|
1 Month Ascribe Chart |
Intraday Ascribe Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/8/2010 | 19:24 | Ascribe.........new to AIM | 11 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 17/8/2010 19:20 by rougepierre I have the riskiest potash exposure in SXX, because I've been convinced for nearly a year that Potash is the next gold. I expect you guys with FX exposure can buy Mosaic or Potash Corp.Meanwhile, can I reiterate my conviction that you should look at any realistic, undervalued Africa met/min/oil/precious stones play for the long haul because it's probably months at most before the Chinese hoover starts to suck. Once there's a significant acquisition they'll be taken out like 9 pins for all the valid reasons why Mac doesn't play AIM...the whole bloody market is massively oversold. Imagine if either your favourite African plays got taken out and/or found committed development and production capital....Look at the takeout price VED is paying for Cairn; and the price DNX is demanding from KNOC... so here's an interesting post on the theme that I found elsewhere: And yes I do hold RRL and separately AFR is my favourite Chinese target in Africa (plus jv opportunities with LONR...) |
Posted at 17/12/2004 08:27 by currypasty Ascribe, the health IT group focusing on medicines management, today announcesthe commencement of dealings of its Ordinary Shares on the AIM market (AIM) of the London Stock Exchange. Seymour Pierce is acting as Nominated Adviser and as Broker to the Company. The stock market EPIC will be ASP.L. Placing Statistics Total number of New Ordinary Shares being placed on behalf of the Company 27,777,778 Number of Sale Shares being placed on behalf of Selling Shareholders 2,777,778 Total number of Ordinary Shares being placed 30,555,556 Issue Price 18p Number of Ordinary Shares in issue immediately following Admission 103,441,732 Percentage of the Enlarged Share Capital being placed 29.5% Market capitalisation at the Issue Price #18.6 million Gross proceeds of the Placing receivable by the Company #5 million Reasons for Admission to AIM and use of proceeds of the Placing The proceeds of the Placing of the New Ordinary Shares, expected to amount to #5 million (before expenses) will be used by the Company, amongst other things, to fund the acquisition of Protechnic Exeter Limited. Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: "We are delighted that the flotation of the Company has been completed successfully. The listing will enable us to take Ascribe to the next stage of its development and maximise any acquisition opportunities for the Company within the international healthcare market. Our strategy is to build on our position in the medicines management market through organic growth and through a number of acquisitions of profitable companies, such as Protechnic Exeter, which offer complementary established systems to customers needing a medicines management solution." |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
